Jenny Chang, MD
Medical Oncology · Houston, TXNPI 1487734810
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $55,981 of the $65,121 with a category attached, or 86.0%. It is spread thinly across 15 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2019 at $29,557 and has fallen 72.7% since, to $8,059 in 2024.
Across 83 payments — averaging $784.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$15K
- AstraZeneca$13K
- Bristol Myers Squibb$7K
- Genentech USA, Inc.$6K
- Novartis$6K
- Eli Lilly$6K
- plus $12K from 9 others
Across 68 payments — averaging $261,116 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$9.5M
- Merck$5.8M
- Novartis$2M
- Takeda Pharmaceuticals U.S.A., Inc.$346K
- Bristol Myers Squibb$54K
- Genentech, Inc.$18K
- plus $10K from 2 others
What the payments were for
- Consulting fees$55,98186%
- Speaking & faculty fees$4,3257%
- Travel & lodging$2,7554%
- Food & beverage$1,8473%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 11 | $15,315 |
| AstraZeneca | 15 | $13,467 |
| Bristol Myers Squibb | 6 | $7,064 |
| Genentech USA, Inc. | 4 | $6,389 |
| Novartis | 5 | $5,812 |
| Eli Lilly | 3 | $5,500 |
| E.r. Squibb & Sons, L.L.C. | 8 | $4,637 |
| Merck | 2 | $4,270 |
| Dompe US, Inc. | 2 | $2,184 |
| Pfizer | 20 | $192 |
| Daiichi Sankyo Inc. | 1 | $137 |
| Stimwave Technologies Incorporated | 1 | $52 |
| Stemline Therapeutics Inc. | 1 | $48 |
| Tactile Systems Technology Inc | 3 | $42 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,121 in reported general payments places this provider in the 80th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TruqapCapivasertib | 14 | $316,734 |
| IbrancePalbociclib | 19 | $291,973 |
| ArimidexAnastrozole | 11 | $16,643 |
| Exemestane | 28 | $7,420 |
| Tamoxifen Citrate | 116 | $2,585 |
| Anastrozole | 122 | $2,104 |
| Letrozole | 19 | $526 |
| Ondansetron OdtOndansetron | 13 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTruqap | $13,467 | $316,73414 claims |
| PfizerIbrance | $192 | $291,97319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.